INS and metabolic dysfunction-associated steatohepatitis: The current clinical strategy for the treatment of NASH is to use insulin sensitizers, hypolipidemic drugs and anti-inflammatory drugs to improve the metabolic syndrome and improve liver function, which lacks the specific treatment of NASH (Targher et al., 2021).